Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022989 | 0.94 | HTR6 (0.53) | HTR6HTR2C | |
| SCHEMBL3948426 | 0.90 | HTR6 (0.51) | HTR6HTR2C | |
| SCHEMBL4026117 | 0.90 | HTR6 (0.55) | HTR6 | |
| SCHEMBL12316138 | 0.89 | HTR6 (0.54) | HTR6HTR2C | |
| SCHEMBL4028239 | 0.83 | HTR6 (0.51) | HTR6 | |
| SCHEMBL4029304 | 0.83 | HTR6 (0.56) | HTR6HTR2C | |
| SCHEMBL3872963 | 0.78 | HTR6 (0.42) | HTR6HTR2C | |
| SCHEMBL10240490 | 0.76 | ACLY (0.47) | HTR6HTR2C | |
| Hydrochloric Acid SCHEMBL9958746 | 0.75 | ACLY (0.47) | HTR6HTR2C | |
| SCHEMBL13900043 | 0.74 | HTR6 (0.57) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | claimed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885HTR2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.